145 related articles for article (PubMed ID: 31295464)
1. Characterization of the in vitro CYP450 mediated metabolism of the polymorphic CYP2D6 probe drug codeine in horses.
Knych HK; Baden RW; Gretler SR; McKemie DS
Biochem Pharmacol; 2019 Oct; 168():184-192. PubMed ID: 31295464
[TBL] [Abstract][Full Text] [Related]
2. Functional phenotyping of the CYP2D6 probe drug codeine in the horse.
Gretler SR; Finno CJ; Kass PH; Knych HK
BMC Vet Res; 2021 Feb; 17(1):77. PubMed ID: 33581736
[TBL] [Abstract][Full Text] [Related]
3. Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity.
Caraco Y; Tateishi T; Guengerich FP; Wood AJ
Drug Metab Dispos; 1996 Jul; 24(7):761-4. PubMed ID: 8818573
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of the enzymes responsible for the metabolism of the non-steroidal anti-inflammatory drugs, flunixin meglumine and phenylbutazone, in horses.
Knych HK; Finno CJ; Baden R; Arthur RM; McKemie DS
J Vet Pharmacol Ther; 2021 Jan; 44(1):36-46. PubMed ID: 32757313
[TBL] [Abstract][Full Text] [Related]
7. A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine.
Pai HV; Kommaddi RP; Chinta SJ; Mori T; Boyd MR; Ravindranath V
J Biol Chem; 2004 Jun; 279(26):27383-9. PubMed ID: 15051713
[TBL] [Abstract][Full Text] [Related]
8. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI).
Dayer P; Desmeules J; Leemann T; Striberni R
Biochem Biophys Res Commun; 1988 Apr; 152(1):411-6. PubMed ID: 3358767
[TBL] [Abstract][Full Text] [Related]
9. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
[TBL] [Abstract][Full Text] [Related]
10. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
11. Identification and kinetics of microsomal and recombinant equine liver cytochrome P450 enzymes responsible for in vitro metabolism of omeprazole.
Ferlini Agne G; Somogyi AA; Sykes B; Knych H; Franklin S
Biochem Pharmacol; 2023 Aug; 214():115635. PubMed ID: 37285945
[TBL] [Abstract][Full Text] [Related]
12. The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites.
Chapron BD; Dinh JC; Toren PC; Gaedigk A; Leeder JS
Drug Metab Dispos; 2020 Nov; 48(11):1113-1120. PubMed ID: 32847865
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition.
Eissing T; Lippert J; Willmann S
Mol Diagn Ther; 2012 Feb; 16(1):43-53. PubMed ID: 22352453
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
[TBL] [Abstract][Full Text] [Related]
15. Equine uridine diphospho-glucuronosyltransferase 1A1, 2A1, 2B4, 2B31: cDNA cloning, expression and initial characterization of morphine metabolism.
Hamamoto-Hardman BD; Baden RW; McKemie DS; Knych HK
Vet Anaesth Analg; 2020 Nov; 47(6):763-772. PubMed ID: 32933848
[TBL] [Abstract][Full Text] [Related]
16. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
Emoto C; Iwasaki K
Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
[TBL] [Abstract][Full Text] [Related]
17. Complementary DNA cloning, functional expression and characterization of a novel cytochrome P450, CYP2D50, from equine liver.
DiMaio Knych HK; Stanley SD
Biochem Pharmacol; 2008 Oct; 76(7):904-11. PubMed ID: 18692486
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.
Desta Z; Ward BA; Soukhova NV; Flockhart DA
J Pharmacol Exp Ther; 2004 Sep; 310(3):1062-75. PubMed ID: 15159443
[TBL] [Abstract][Full Text] [Related]
19. In vitro characterization of 4'-(p-toluenesulfonylamide)-4-hydroxychalcone using human liver microsomes and recombinant cytochrome P450s.
Lee B; Wu Z; Lee T; Tan XF; Park KH; Liu KH
Xenobiotica; 2016; 46(4):350-6. PubMed ID: 26330107
[TBL] [Abstract][Full Text] [Related]
20. On the assessment of drug metabolism by assays of codeine and its main metabolites.
Haffen E; Paintaud G; Berard M; Masuyer C; Bechtel Y; Bechtel PR
Ther Drug Monit; 2000 Jun; 22(3):258-65. PubMed ID: 10850391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
